More info
Novel GluN2B-specific NMDAR antagonist, completely preventing the decrease in insulin secretion of about 32 % provoked by a 24-h-treatment with NMDA/glycine, eliminating NMDA-induced changes in the oxidation status of the islet cells and elevating the sensitivity of intracellular calciumto 15 mM glucose